Skip to main content
. 2018 Dec 1;25(6):e499–e506. doi: 10.3747/co.25.4102

TABLE II.

Adjuvant chemotherapy: use, completion rate, and toxicity

Variable Age group p Valuea


Overall <65 Years 65–69 Years ≥70 Years 65–69 Years ≥70 Years
Patients (n) 134 286 60 92

Adjuvant CTx [n (%)] 177 (62) 109(81) 41 (68) 27 (29) 0.063 <0.001

CTx regimen [n (%)]
 Capecitabine 79 (45) 45 (41) 24 (59) 10 (37)
 FUFA, 5FUb 63 (36) 38 (35) 12 (29) 13 (48)
 XELOX 11 (6) 7 (6) 3 (7) 1 (4)
 FOLFOX 12 (7) 10 (9) 2 (5) 0 (0)
 Other 17 (10) 12 (11) 1 (2) 4 (15)

Completion [n (%)] 116 (66) 76 (70) 26 (65) 14 (52) 0.089 <0.001

Dose reduction [n (%)] 71 (40) 40 (38) 14 (35) 17 (68) 0.390 0.062

Delay [n (%)] 58 (33) 40 (38) 11 (28) 7 (28) 0.112 <0.001

Regimen change [n (%)] 10 (6) 9 (8) 0 (0) 1 (4) 0.059 0.051

Toxicity [n (%)] 125 (71) 74 (68) 28 (70) 23 (85) 0.281 <0.001
 Mucositis 31 20 5 6
 Diarrhea 39 20 11 8
 Anorexia 27 13 6 8
 Nausea, vomiting, or both 23 18 2 3
 Hand–foot 31 17 12 2
 Fever 13 7 3 3

Toxicity grade [n (%)]
 1 44 (35) 33 (45) 5 (18) 6 (26)
 2 59 (47) 29 (39) 19 (68) 11 (48) 0.008 0.274
 ≥3 22 (18) 12 (16) 4 (14) 6 (26) 0.424 0.165

Hospitalization 18 (10) 11 (10) 3 (7) 4 (14) 0.752 0.750
a

Comparing the older age group with the group less than 65 years of age. Significant values appear in boldface type.

CTx = chemotherapy; FUFA= 5-fluorouracil–folinic acid; 5FUb= 5-fluorouracil bolus; XELOX = capecitabine–oxaliplatin; FOLFOX= 5-fluorouracil–oxaliplatin.